462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI